Fundz

Ensoma, Inc. reported raising $129 Million in an initial SEC Form D filing, from an offering of $70.5 Million

PRIVATEFeb 19, 2021

Amount Raised

$129 Million

$129 Million sold, per SEC Form D (first sale Feb 19, 2021)

Round Type

Venture

BostonBiotechnologyHealth Care

Who else raised in Biotechnology and Health Care around the same time

Companies in the same sectors as Ensoma that raised within 45 days of this round, from Fundz verified event records.

  • Artiva Biotherapeutics raised $120M on April 5, 2021.
  • LianBio raised $3M (Seed) on April 5, 2021.
  • GUIDED THERAPEUTICS INC raised $2.1M (Series F) on March 31, 2021.
  • Trait Biosciences Inc. raised $12M on March 31, 2021.
  • City of Hope raised $50M (Funding Round) on March 31, 2021.
  • Health Plix raised $14M (Funding Round) on March 31, 2021.

Who to call at Ensoma, and when

A new round usually means Ensoma is about to hire and buy. The teams that reach out first get the meeting.

  • An alert the day Ensoma raises, hires an executive or expands, scored against what you sell
  • The decision-makers there, with verified emails
  • Who you already know at Ensoma, from your own LinkedIn network

Works inside ChatGPT and Claude. Ask who to call at Ensoma. With Fundz connected, it knows.

Watch Fundz in
See plan options
Trusted byOracleSnowflakeCloudflareLinkedInGoogleSalesforce 4.8/5 on G2

Company Information

Company

Ensoma

Location

Boston, Massachusetts, United States

About

Ensoma is developing potentially curative medicines for genetic diseases, immune disorders and cancer through in vivo hematopoietic stem cells (HSCs) engineering. Our platform combines proprietary base editing or high-efficiency gene integration systems with high-capacity virus-like particles (VLPs) toward our goal of providing one-time administration of durable genetic medicines. The delivery system is based on VLPs that preferentially bind to HSCs, delivering DNA to the nucleus. With a 35-kilobase cargo capacity, these VLPs can carry a diverse range of sophisticated genomic engineering tools capable of introducing changes from single base edits to large multi-gene insertions, along with control elements for HSC-lineage cell specific expression. Ensoma is supported by top-tier investors and a passionate team committed to a bold, global vision for genetic medicines.

AI made execution free. Knowing first is the whole game now.

Fundz sees it the moment Ensoma raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.

Related People

2 contacts
Verified contacts hidden hidden hidden hiddenSee plans and pricing
Predictive Intelligence
Strategic

ML-powered predictions for Ensoma's next move

See what Strategic adds

Ensoma raised. Fundz records a round at a median of 3.6 minutes from the SEC filing, with the decision-maker attached.

145 of these a day, filtered to the companies you pick, with the decision-maker attached.

5 screens from a live account. No signup.

Fundz is a real-time business intelligence platform powered by agentic AI that proactively delivers personalized daily signals, including funding rounds, executive changes, M&A activity, 13F institutional filings, SEC 8-K events, investor activity, and website modifications, based on each user's watchlist and ICP. A trusted data source at firms such as BlackRock, Oracle, Kleiner Perkins, LinkedIn, HubSpot, and Cloudflare, Fundz democratizes the institutional-grade intelligence that previously required a PitchBook or Bloomberg terminal. Features include Daily Briefing for AI-powered daily briefings, and unified cross-signal alerts across 281,000+ organizations. Developers and data teams can access these signals programmatically via the Fundz Funding Data API, with transparent published pricing.